Sibutramine
Sources
registry, as of 2010-05-11Stale
https://clinicaltrials.gov/study/NCT00234832
A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 10777. Conditions Obesity. The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event. diarrhea Lead-in Period Sibutramine 0 nausea Lead-in Period Sibutramine 0 vomiting Lead-in Period Sibutramine 0 diarrhea Randomized Sibutramine 4 nausea Randomized Sibutramine 2 vomiting Randomized Sibutramine 1 diarrhea Randomized Placebo 7 nausea Randomized Placebo 5 vomiting Randomized Placebo 5
ClinicalTrials.gov NCT00234832 protocol and results modules
registry, as of 2007-08-31Stale
https://clinicaltrials.gov/study/NCT00261911
A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 498. Conditions Obesity. The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents.
ClinicalTrials.gov NCT00261911 protocol and results modules
registry, as of 2008-03-27Stale
https://clinicaltrials.gov/study/NCT00645255
Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects. Overall status TERMINATED. Phases PHASE3. Lead sponsor Abbott. Enrollment 466. Conditions Obesity; Weight Loss. The study was designed to evaluate the long term efficacy and safety of Meridia 15 mg daily in obese subjects.
ClinicalTrials.gov NCT00645255 protocol and results modules
registry, as of 2007-08-31Stale
https://clinicaltrials.gov/study/NCT00402584
A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 304. Conditions Binge Eating Disorder; Obesity. The purpose of this study is to examine the safety and efficacy of sibutramine in preventing binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of sibutramine in reducing body weight in subjects with binge-eating disorder.
ClinicalTrials.gov NCT00402584 protocol and results modules
registry, as of 2009-08-12Stale
https://clinicaltrials.gov/study/NCT00134199
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects. Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Pfizer. Enrollment 282. Conditions Obesity. To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP * the relationship between the conce
ClinicalTrials.gov NCT00134199 protocol and results modules
registry, as of 2008-05-19Stale
https://clinicaltrials.gov/study/NCT00679653
Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 171. Conditions Obesity; Hypertension. To study the effect of sibutramine treatment on weight reduction and blood pressure improvement in three groups with antihypertensive therapy whose blood pressure was not adequately controlled with antihypertensive combination treatment.
ClinicalTrials.gov NCT00679653 protocol and results modules
registry, as of 2008-05-14Stale
https://clinicaltrials.gov/study/NCT00677391
Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 103. Conditions Obesity. The primary objective of this study was to evaluate the efficacy and the safety of sibutramine vs. placebo in combination with a hypocaloric diet on weight-loss in overweight and obese Malaysian subjects.
ClinicalTrials.gov NCT00677391 protocol and results modules
registry, as of 2009-07-17Stale
https://clinicaltrials.gov/study/NCT00941382
Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Laboratorios Silanes S.A. de C.V.. Enrollment 60. Conditions Obesity. The aim of this study is to evaluate the effect of sibutramine and metformin combination therapy in comparison with sibutramine or metformin monotherapy over weight, adiposity, glucose metabolism and inflammatory state in obese patients.
ClinicalTrials.gov NCT00941382 protocol and results modules
publication, as of 2004-05-21Stale
https://pubmed.ncbi.nlm.nih.gov/15013931/
Sibutramine and the management of obesity. Sibutramine is a selective serotonin and noradrenaline re-uptake inhibitor approved for the long-term management of obesity. Its primary mechanism of action is increased satiety, although some evidence also suggests increased energy expenditure could pla
PMID 15013931